from AFR:
an upcoming ASX IPO company Triad Life Sciences was valued at $500m but the IPO plan was halted because its board is considering a takeover bid with 30% premium, giving the company an implied value of $650m.
taking an extremely conservative approach, assuming ARX is same as Triad, this alone will give ARX a sp of above $1.9 and moreover:
I have checked Triad website and find limited info (I personally feel much of it just bluffing and lack of substantiation). have a look urself.
my understanding is Triad, as a later comer, has not (or just planned to) commercialize its product, whist ARX has a range of commercialize products with proven effectiveness, a deployed and active sales team, distribution contracts with reputable distribution network, high gross margin, stable royalties, no debts and no capital raising on the road to profitability.
I do think ARX cap should be much higher than $650m valuation given to Triad. I think ARX is a hidden gem sooner or later to be found by more investors.
DYOR AND GLTA.
Come on finish $5 plus, page-38
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARX (ASX) to my watchlist
|
|||||
Last
59.0¢ |
Change
-0.010(1.67%) |
Mkt cap ! $203.0M |
Open | High | Low | Value | Volume |
59.0¢ | 59.5¢ | 57.5¢ | $785.7K | 1.398M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 345 | 59.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
60.0¢ | 1000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 345 | 0.590 |
1 | 7073 | 0.585 |
1 | 1724 | 0.580 |
2 | 17108 | 0.575 |
1 | 40000 | 0.570 |
Price($) | Vol. | No. |
---|---|---|
0.600 | 1000 | 1 |
0.620 | 62127 | 4 |
0.640 | 29999 | 1 |
0.645 | 16108 | 2 |
0.650 | 45000 | 2 |
Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
Featured News
ARX (ASX) Chart |